TILs for the Treatment of Solid Tumors with KSQ Therapeutics' Micah Benson, Ph.D. 

KSQ Therapeutics' CSO, Micah Benson, Ph.D., joins Erin Harris to discuss how Tumor-Infiltrating Lymphocytes (TILs) as a treatment modality have the potential to treat a variety of solid tumor types. Benson explains KSQ's Phase 1/2 clinical study, KSQ-001EX, which consists of TILs in which the SOCS1 gene is inactivated by CRISPR/Cas9 gene editing. In addition to solid tumors, Benson also addresses the therapeutic potential for autoimmune disease.
--
#celltherapy #genetherapy
Subscribe to the podcast!
Apple - podcasts.apple...
Spotify - open.spotify.c...
RU-vid - • Cell & Gene The Podcast